Melissa Badamo

DocwireNews

Hydroxyurea treatment reduced the incidence of blood transfusion by 75% among pediatric patients in sub-Saharan Africa with <a href="https://www.docwirenews.com/page/sickle-cell-disease">sickle cell anemia</a>, according to the phase I/II REACH trial.The <a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.27244" target="_blank" rel="noopener">study</a> was led by Alexandra Power-Hays, MD, of the Cincinnati Children&rsquo;s Hospital Medical Center, and published in the American Journal of Hematology.Dr. Power-Hays and colleagues evaluated transfusion utilization in children with sickle cell anemia before and during hydroxyurea treatment. Risk factors for higher transfusion rates include younger age at enrollment, lower hemoglobin, and palpable splenomegaly.<h2>Hydroxyurea Significantly Reduces Transfusions in Sickle Cell Disease</h2>Following a pretreatment screening period of two months, patients received six&thinsp;months of hydroxyurea at a fixed dose of 15 to 20&thinsp;mg/kg/day, 18&thinsp;months of dose escalation, then stable dosing at the maximum tolerated dose (MTD).A total of 545 transfusions were administered to 258 of 635 (40.4%) patients, and 133 (20.9%) patients received two or more transfusions. The transfusion rate per 100 person-years was 43.2 before hydroxyurea, 21.7 on fixed dose, 14.5 during dose escalation, and 10.8 on MTD.MTD treatment reduced transfusion rate by 75% compared with the pretreatment period (IRR 0.25, 95% confidence interval [CI] 0.18&ndash;0.35, P&lt;0.0001), and by 50% compared with fixed dose treatment (IRR 0.50, 95% CI 0.39&ndash;0.63, P&lt;0.0001).&ldquo;If widely implemented, universal testing and hydroxyurea treatment at MTD could potentially prevent 21% of all pediatric transfusions administered in sub-Saharan Africa,&rdquo; wrote Dr. Power-Hays and colleagues.Recurrent transfusions can contribute to iron overload, erythrocyte alloimmunization, and non-immune hemolytic transfusion reactions, according to the authors. &ldquo;Increasing hydroxyurea access for [sickle cell anemia] should decrease the transfusion burden and increase the overall blood supply,&rdquo; they concluded.Related: <a href="https://www.docwirenews.com/post/could-isoquercetin-solve-thromboinflammation-in-sickle-cell-disease">Could Isoquercetin Solve Thromboinflammation in Sickle Cell Disease?</a>ReferencePower-Hays A, Tomlinson GA, Tshilolo L, et al. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: analysis from the phase I/II REACH trial. Am J Hematol. 2024. doi.org/10.1002/ajh.27244

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Hydroxyurea Reduces Transfusion Requirements in Children With Sickle Cell Anemia

Sickle Cell Disease

Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe